NUAK2 and hepatocellular carcinoma: For example, NUAK2 has been identified as a critical downstream target of YAP during liver tumorigenesis, and pharmacological inhibition of NUAK2 suppressed YAP-driven tumor growth in vivo.402 NIBR-LTSi, a selective small-molecule LATS kinase inhibitor was characterized to activate YAP signaling and blocks differentiation in vitro and in vivo, also accelerate liver regeneration following extended hepatectomy in mice,403 suggesting a clinical potential after resection therapy for HCC.